Subscribe to Search results

Within Vaughan Gething's oral evidence to the Inquiry he called the Enhanced Hepatitis Stage 1+ payment an understanding of the hurt that people had already gone through.

Published on:

In her oral evidence to the Inquiry, Samantha Baker confirmed that by the end of 2020 there had been no significant progress or developments regarding the achievement of parity.

Published on:

The move towards greater parity between the four national schemes gathered momentum in March 2021.

Published on:

In his oral evidence to the Inquiry, Martin Bell confirmed that SIBSS would assist potential beneficiaries to access their medical records during the application process for the scheme by speaking to the GP or health board.

Published on:

Dr Walford was clear that the medical stream of the civil servants of the DHSS believed that the likeliest cause of AIDS was an infective agent.

Published on:

Dr Diana Walford described the delay in construction of new facilities for PBL production as "unconscionable".

Published on:

Dr Walford described the Deputy CMO, Dr Harris, as "exasperated" because of the Ministers decision to defer the eventual decision on whether to build a new laboratory within the NHS.

Published on:

Dr Vaughan announced that there would be "no commercial management of Blood Products Laboratory: modernisation programme already underway."

Published on:

Dr Walford remembered her frustration about "innumerable and repetitive meetings which generally ended without moving matters forward to any appreciable extent."

Published on:

A special health authority was established to take responsibility for the management of the BPL, the PFL in Oxford and the Blood Reference Group Laboratory.

Published on:

Dr Walford said that Dr Lane was right to describe the difficulties in meeting the problems of the NBTS as having been "accentuated by the growth in requirement during the 1970s of plasma products, an exercise in production maintained without adequate planning, co-ordination or finance from the outset."

Published on:

Regional health authorities were described by Dr Walford as "fiefdoms".

Published on:

Dr Walford described the process in deciding to develop BPL as "totally chaotic, protracted and difficult" and "needlessly so".

Published on:

Dr Walford described the delays between April 1979, when the Medicines Inspectorate conducted their inspection and condemned the premises operated for BPL as unsuitable for a pharmaceutical company, and the middle of May 1983, when construction began as "unconscionable".

Published on:

The estimate of £6-7 million put a stop to any further discussions with Scotland regarding plans for the redevelopment of BPL and was described by Dr Walford as "a sort of bitter blow".

Published on:

According to Dr Diana Walford's oral evidence, the Morbidity and Mortality Weekly Report was received in the Med IMCD and the expectation would be that it should have been referred to the Med SEB because it concerned blood and blood products.

Published on:

Dr Clarke was copied into correspondence as the doctor covering for Dr Diana Walford in Med SEB while Dr Walford was on maternity leave.

Published on:

According to Dr Diana Walford's oral evidence, following reading about the case of the baby who contracted AIDS through platelets transfusion she had the sense that AIDS was transmitted through blood and blood products.

Published on:

According to Dr Diana Walford's oral evidence, AIDS was one of the primary concerns of Med SEB and Med ICMD.

Published on:

According to Dr Diana Walford's oral evidence, there was no formal consideration of strategies that could have been devised to reduce reliance on commercial concentrates and it was thought to be logistically impossible to switch to cryoprecipitate use at the level that was needed.

Published on: